dihexa pnb 0408 human trial trials Dihexa (also known as PNB-0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the blood–brain barrier and has shown synaptogenic effects in preclinical Dihexa UK: Evidence-Based Peptide Research
Description
Count: 10 Multiple Dose Vials Per Tray
It is non-pyrogenic and isotonic, supporting osmotic conditions compatible with many research preparations
Not for medical purposes
Given Dihexa's long half-life (approximately 12 days), some providers use intermittent dosing schedules at the 25mg level, such as 5 days on / 2 days off, to manage steady-state accumulation
